Hyperspectral imaging to guide robot-assisted kidney tumor removal

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study will use hyperspectral imaging during robot-assisted partial nephrectomy to map tissue properties and blood flow in the kidney. Researchers will compare hyperspectral patterns with tumor type and tissue perfusion to see if the imaging can aid surgical decisions. The study will enroll adults with a kidney tumor ≤7 cm who are planned for robotic partial nephrectomy at the University Hospital Leipzig. The goal is to determine whether hyperspectral imaging can provide real-time information to support selective tumor removal while sparing healthy kidney tissue. No interventional treatments are being tested beyond the imaging modality.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a kidney tumor ≤7cm
* planned robot-assisted partial nephrectomy
* age ≥ 18 years

Exclusion Criteria:

* patients with a previous surgery on the affected kidney
* patients with a fully intrarenal/endophytic tumor without an exophytic component
* previous malignancy with ongoing or planned nephrotoxic chemotherapy
* current immunosuppression (e.g., organ transplantation, leukemia)
* pregnancy, lactation, or women who wish to have children
* inability to give informed consent

Where it's running

• University Hospital Leipzig
  Leipzig, Germany Recruiting

Study contacts

• Study coordinator: Jens-Uwe Stolzenburg, Professor Dr.
• Email: jens-uwe.stolzenburg@medizin.uni-leipzig.de
• Phone: +49 3419717600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRI-based AI to classify and grade renal tumors

  This study tests AI methods on MRI data from adults with kidney tumors to see if they can identify tumor type and grade before surgery.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07743749

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

• Comparing back (SARA) versus side (flank) positions for single-port robotic partial kidney tumor removal.

  This will see if placing adults on their back using the SARA technique or on their side leads to fewer complications and faster recovery for people having single-port robotic partial nephrectomy for small kidney tumors.

  Recruiting Niguarda Hospital · Milan · NCT07234409

• Treating the main kidney tumor in metastatic kidney cancer during immunotherapy

  This trial will see if adding surgery or radiotherapy to the main kidney tumor helps people with metastatic clear‑cell kidney cancer who are already benefiting from anti‑PD1–based therapy live longer.

  Recruiting Phase 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06903312

• Comparing systemic treatment alone to systemic treatment with added radiotherapy for kidney cancer with few metastases

  This study is testing if adding targeted radiation therapy to regular treatment can help people with kidney cancer that has spread a little to live longer without their cancer getting worse.

  Recruiting Phase 3 Samsung Medical Center · Seoul · NCT06467097

• Impact of kidney function on cancer drug levels in patients with metastatic kidney cancer

  This study is testing how kidney function affects the levels of cancer drugs in the blood for patients with metastatic kidney cancer to see if they need different doses for better results.

  Recruiting at 5 sites Institut du Cancer de Montpellier - Val d'Aurelle · Marseille and 4 other locations · NCT04823923

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.